Explore Business Standard
Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w
Tripura Chief Minister Manik Saha launched a state-wide intensified information education and communication (IEC) campaign to raise mass awareness among the people of the state about HIV and AIDS. Launching the campaign on Saturday, the CM stressed on the importance of public awareness and precautionary measures needed to check and control the spread of HIV infection. Before launching the awareness programme, Saha held a review meeting on HIV/AIDS-related issues at the Civil Secretariat on Saturday. "Chaired a review meeting of the Tripura State AIDS Control Society at the Secretariat, discussing progress, challenges, and future strategies to combat HIV/AIDS in the state. The meeting discussed the progress, challenges and future strategies to combat HIV/AIDS in the state. "Committed to ensuring quality healthcare and support services to all and achieve the target of ending HIV/ AIDS by 2030!" the chief minister said in a post on X. In the meeting, the CM said, "Students from schoo
The Delhi High Court will take up and dispose of on priority basis the legal proceedings concerning an HIV positive person whose anonymity and confidentiality shall be strictly maintained. The practice directions' have been issued by the high court, on its administrative side, in compliance with the directions passed by the Supreme Court in a judgment on September 26, 2023. In compliance of the directions passed by the Hon'ble Supreme Court in judgment dated September 26, 2023 in , Hon'ble the Acting Chief Justice has been pleased to issue following directions for compliance by all concerned. In any legal proceeding concerning or relating to an HIV-positive person, the courts shall take up and dispose of the proceeding on priority basis in terms of Section 34(2) of the HIV (Prevention and Control) ACT 2017, the practice directions issued through Delhi High Court Registrar General Kanwaljeet Arora on February 7 said. It further said that courts shall also ensure that the anonymity a
Delhi High Court has directed the city government to ensure free food and medical treatment to HIV-positive persons living below the poverty line and strictly comply with the law dealing with the affected patients' grievances. A bench headed by Chief Justice Satish Chandra Sharma observed that several rehabilitative schemes and measures, including affordable treatment, had been put in place by the Delhi government to provide aid and assistance to HIV-positive patients and it was ensuring strict compliance under the Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017. "It is abundantly evident that the GNCTD is ensuring strict compliance under the statutory provisions of the 2017 Act. Further, the GNCTD has taken all possible steps to ensure that affordable treatment is available to individuals afflicted with HIV/AIDS, who do not possess the financial wherewithal to do so," the bench also comprising Justice Subramonium Prasad said in